Page 212 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GELMC
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia
E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH,
Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A,
Quenet S, Bédoucha V, Mauro MJ.
• Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-
Toxicity with Tyrosine Kinase Inhibitors.
Cancers (Basel). 2023;15(4):1045. doi: 10.3390/cancers15041045.
Pérez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, Pérez López R, Ruiz Nuño C, De
Las Heras N, Mora Casterá E, López Marín J, Segura Díaz A, Gómez V, Vélez Tenza
P, Sierra Pacho M, Vera Goñi JA, Moreno Vega M, Álvarez-Larrán A, Cortés M, Pérez
Encinas M, Carrascosa Mastell P, Angona A, Rosell A, Lakhwani S, Colorado M, Ramila
E, Cervero C, Cuevas B, Villalón Blanco L, de Paz R, Paz Coll A, Fernández MJ, Felipe
Casado L, Alonso-Domínguez JM, Anguita Arance MM, Salamanca Cuenca A, Jiménez-
Velasco A, Prendes SO, Santaliestra M, Lis Chulvi MJ, Hernández-Boluda JC, García-
Gutiérrez V.
• Treatment-free remission after dasatinib in patients with chronic myeloid leukemia
in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol. 2023;202(5):942-52. doi: 10.1111/bjh.18883.
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon
FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martín-Regueira P, Lipton JH.
• Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases
Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.
Cancers (Basel). 2023;15(13):3384. doi: 10.3390/cancers15133384.
Stuckey R, Segura-Díaz A, Sáez Perdomo MN, Pérez Encinas MM, González San Miguel
JD, Florido Y, Sánchez-Sosa S, López-Rodríguez JF, Bilbao-Sieyro C, Gómez-Casares MT;
Spanish CML Group (GELMC).
Comunicaciones orales
Congresos internacionales
• S153. Mechanisms of Trombogenesis in Patients With Chronic Myeloid Leukemia
Under Treatment With Ponatinib and Other Tyrosine Kinase Inhibitors.
28th Congress of the European Hematology Association (EHA). EHA2023 Frankfurt &
Virtual, Jun (8-11).
212